65. Pirraglia P.A., Stafford R.S., Singer D.E. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiatry. 2003; 5: 153–7.

66. Brownlee S. Overtreated: why too much medicine is making us sicker and poorer. New York: Bloomsbury; 2007.

67. Boseley S. They said it was safe. The Guardian. 1999 Oct 30.

68. Healy D. Pharmageddon. Berkeley: University of California Press; 2012.

69. Internal Eli Lilly memo. Bad Homburg. 1984 May 25.

70. Virapen J. Side Effects: death. College Station: Virtualbookworm.com Publishing; 2010.

71. Pringle E. Eli Lilly hides data: Zyprexa, Evista, Prozac risk. Conspiracy Planet. Available online at: www.conspiracyplanet.com/channel.cfm?channelid=64228&contentid=64228&page=2 (accessed 28 June 2012).

172. Teicher M.H., Glod C., Cole J.O. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990; 147: 207–10.

173. Lenzer J. FDA to review ‘missing’ drug company documents. BMJ. 2005; 330:7.

174. Bouchy C. Internal Eli Lilly memo. 1990 Nov 13.

175. Rosenbaum J.F., Fava M., Hoog S.L., et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998; 44: 77–87.

176. Barbui C., Cipriani A., Brambilla P., et al. ‘Wish bias’ in antidepressant drug trials? J Clin Psychopharmacol. 2004; 24: 126–30.

177. European Medicines Agency (1999/2000). EMEA/CPMP/2775/99.

178. Lenzer J. Drug secrets: what the FDA isn’t telling. Slate. 2005 Sept 27.

179. Lenzer J. Secret US report surfaces on antidepressants in children. BMJ. 2004; 329: 307.

180. Jurand S.H. Lawsuits over antidepressants claim the drug is worse than the disease. American Association for Justice. 2003 Mar 1. Available online at: www.thefreelibrary.com/_/print/PrintArticle.aspx?id=64228 (accessed 23 December 2012).

181. Barbui C., Furukawa T.A., Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ. 2008; 178: 296–305.

182. Serna M.C., Cruz I., Real J., et al. Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry. 2010; 25: 206–13.

183. Ioannidis J.P.A. Ranking antidepressants. Lancet. 2009; 373: 1759–60.

184. Laughren T.P. Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). 2006 Nov 16. Available online at: www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf (accessed 22 October 2012).

185. Fournier J.C., DeRubeis R.J., Hollon S.D., et al. Antidepressant drug effects and depression severity. A patient-level meta-analysis, JAMA. 2010; 303: 47–53.

186. DeRubeis, Fournier J.C. Depression severity and effect of antidepressant medications. JAMA. 2010; 303: 1599.

187. Johnson L.A. Pfizer disputes claim against antidepressant. USA Today. 2013 Jan 31.

188. Babyak M., Blumenthal J.A., Herman S., et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med. 2000 Sep–Oct; 62:633–8.

189. Rimer J., Dwan K., Lawlor D.A., et al. Exercise for depression. Cochrane Database Syst Rev. 2012; 7: CD004366.

190. Haug T.T., Blomhoff S., Hellstrøm K., et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry. 2003; 182: 312–8.

191. GlaxoSmithKline. Wikipedia 2012; 20 June. Available online at: http://en.wikipedia.org/wiki/GlaxoSmithKline (accessed 20 June 2012).

192. Herxheimer A. Turbulence in UK medicines regulation: A stink about SSRI antidepressants that isn’t going away. Chapter 10. In: Glavanis K, O’Donovan O, editors. Power, Politics and Pharmaceuticals: drug regulation in Ireland in the global context. Cork University Press, 2008.

193. Grassley C.E. Paxil. Speech at the US Senate. 2008 June 11.

194. Riddle M.A., King R.A., Hardin M.T., et al. Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol. 1990/1991; 1: 193–8.

195. Brynner R., Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.

196. Hansen E.H., Gyldmark M. [Psychotropic drug use. Distribution and development]. København: Sundhedsstyrelsen; 1990.

197. Glass J., Lanctôt K.L., Herrmann N., et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefi ts. BMJ. 2005; 331: 1169–73.

198. de Gage S.B., Bégaud B., Bazin F., et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012; 345: e6231.

199. Nielsen M. Selective Serotonin Reuptake Inhibitors (SSRI) – sales, withdrawal reactions and how drug regulators reacted to this with benzodiazepines as comparator [PhD thesis]. Copenhagen: University of Copenhagen; 2013.

100. Fava G.A., Bernardi M., Tomba E., et al. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol. 2007; 10: 835–8.

101. Medawar C. The antidepressant web – marketing depression and making medicines work. Int J Risk Saf Med. 1997; 10: 75–126.

102. Montgomery S.A., Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol. 1993 Fall; 8: 189–95.

103. Geddes J.R., Carney S.M., Davies C., et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003; 361: 653–61.

104. House of Commons Health Committee. The Infl uence of the Pharmaceutical Industry. Fourth Report of Session 2004–05. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf/apr 2005 (accessed 26 April 2005).

Glaxo обманывала даже собственных торговых представителей, говоря им, что испытание 329 «показало ЗАМЕЧАТЕЛЬНУЮ эффективность»3, при этом во внутренних документах признавалась, что эффективность паксила не доказана. Исследование было отрицательным в отношении эффективности по всем восьми исходам и положительным в демонстрации вреда. Эти бесспорные факты были настолько искажены в ходе масштабной манипуляции с данными, что опубликованная статья теневого авторства (имевшая целых 22 «автора») в итоге представила отчет о положительных эффектах3, 4. Массаж данных после их разделения различными способами произвел четыре статистически значимых эффекта, и было ясно, что прежде чем данные были представлены, перепробованы многочисленные варианты. В статье не осталось никаких следов этого; в действительности она ложно утверждала, что положительные исходы были получены априори.